Health care resource utilization in patients with multiple myeloma receiving bispecific antibody therapy with teclistamab: A Medicare claims database analysis in the US Free

Background:

Four bispecific antibodies (bsAbs), teclistamab, elranatamab, talquetamab, and linvoseltamab have been approved for use in the U.S. in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). The objective of this analysis was to describe healthcare resources utilization (HCRU) in Medicare pts initiating treatment (≥1 medical claim) with teclistamab for R/R MM, and to explore how HCRU differs for pts who initiate in the inpatient (IP) vs outpatient (OP) setting. We focused only on teclistamab due to insufficient follow-up for robust analyses of other bsAbs.

Methods:

The study used data from a 100% sample of fee-for-service Medicare enrollment and medical (Parts A and B) claims data during the “study period” spanning from 12 months prior to the approval of teclistamab to the end of availability of claims data (Oct 25, 2021–Sep 30, 2024). The study population included all pts in the database with ≥1 diagnosis of MM and ≥1 claim for teclistamab ≥30 days prior to the end of the study period. Patients were required to be continuously enrolled for Medicare medical benefits for the 12 months up to and including the 1^st claim for teclistamab (the “index date”). Other main eligibility criteria included: 1) index date on/after availability of both IP and OP procedure codes for teclistamab; 2) no claims for MM treatment other than teclistamab or a corticosteroid within 0–30 days post index date; 3) if 1^st administration of teclistamab was in the OP setting, dosage was consistent with first step up dose (SUD) and 4) ≥65 years of age as of index date. For each patient, the follow-up period was defined as the period from the index date to first occurrence of death, end of continuous enrollment, or end of study period. Setting of initiation of treatment was defined based on the setting of the first claim for teclistamab (IP or OP). For pts who initiated teclistamab in the IP setting, completion of SUD was defined as ≥1 OP administration with a full treatment dose of teclistamab (i.e., not an SUD) that occurred ≥10 days post index date. For those who initiated teclistamab in an OP setting, completion of SUD was defined as ≥2 OP administrations of teclistamab at a full treatment dose. The number of hospitalizations and physicians' office and hospital OP visits during teclistamab treatment were calculated on a per patient per month (PPPM) basis.

Results:

A total of 2,185 pts had ≥1 claim for teclistamab during the study period. Of these, 1,373 met all eligibility criteria. Mean (median) age at index date was 75 (74) years and 49% were female. Mean (median [range]) follow-up was 8.2 (7 [0.2–22.7]) months. Overall, 87% of pts initiated teclistamab in an IP setting, with a mean length of stay (LOS) for the index hospitalization of 9.3 days. Among those initiating teclistamab in an OP setting, 41% were hospitalized within 1 month of treatment initiation. Among all pts (IP or OP initiation of treatment), the Kaplan–Meier estimated median duration of teclistamab treatment was 6.1 months; 87% of pts completed SUD. Patients had a mean (median) of 0.72 (0.32) hospitalizations PPPM and 6.4 (5.8) hospital outpatient or physician's office visits PPPM during teclistamab treatment.

Conclusions:Most pts with MM receiving teclistamab initiate treatment in an IP setting, with hospital LOS consistent with dosing guidance from the prescribing information. A substantial proportion of those who initiate teclistamab in an OP setting are hospitalized within 30 days. Treatment duration and percentage of pts completing SUD were consistent with values in other real-world studies of teclistamab. Patients receiving teclistamab have a high hospitalization burden during treatment initiation and frequent hospitalizations and OP visits over the course of treatment. These results highlight the need for novel treatments, administration models, and/or implementation of standardized supportive care guidelines to reduce the hospital burden and increase time on treatment for pts receiving bsAbs in real world settings.